Anti- Activity Enhancement of Curcumin by Its Monoketone Tetramethoxy Analog Diveratralacetone

Overview

Journal Curr Res Parasitol Vector Borne Dis

Date 2022 Mar 14

PMID 35284878

Authors

Julia M Souza

Tatiana M Vieira

Ana Carolina B B Candido

Daiane Y Tezuka

G Subba Rao

Sergio de Albuquerque

Antonio E M Crotti

Jair L Siqueira-Neto

Lizandra G Magalhaes

Affiliations

Soon will be listed here.

Abstract

Chagas disease is a tropical disease caused by the protozoan parasite and currently affects millions of people worldwide. Curcumin (CUR), the major constituent of turmeric spice (dry powder of L. plant rhizomes and roots), exhibits antiparasitic activity against protozoan parasites . However, because of its chemical instability, poor cellular uptake and limited bioavailability it is not suitable for clinical use. The objective of this study was to synthesize and evaluate CUR monoketone analog dibenzalacetone (DBA ) and its non-phenolic, methoxy () and chloro () derivatives for better stability and bioavailability against . Diveratralacetone, the tetramethoxy DBA (DBA ), was found to be the CUR analog with most enhanced activity against the amastigote forms of four strains of tested (Brazil, CA-I/72, Sylvio X10/4 and Sylvio X10/7) with 50% inhibitory concentration (IC) < 10 μM (1.51-9.63 μM) and selectivity index (SI) > 10 (C2C12 non-infected mammalian cells). This was supplemented by time-course assessment of its anti- activity. DBA and its dimethoxy (DBA ) and hexamethoxy (DBA ) derivatives were substantially less active. The inactivity of dichloro-DBA (DBA ) was indicative of the important role played by oxygenated groups such as methoxy in the terminal aromatic rings in the DBA molecule, particularly at position to form reactive oxygen species essential for anti- activity. Although the DBAs and CUR were toxic to infected mammalian cells , in a mouse model, both DBA and CUR did not exhibit acute toxicity or mortality. These results justify further optimization and anti- activity evaluation of the inexpensive diveratralacetone for its potential use in treating Chagas disease, a neglected parasitic disease in economically challenged tropical countries.

Citing Articles

Exploring Synthetic Dihydrobenzofuran and Benzofuran Neolignans as Antiprotozoal Agents against .

Pagotti M, Dias H, Candido A, Oliveira T, Borges A, Oliveira N Pharmaceutics. 2023; 15(3).

PMID: 36986617 PMC: 10052957. DOI: 10.3390/pharmaceutics15030754.

Structure-activity relationship of dibenzylideneacetone analogs against the neglected disease pathogen, Trypanosoma brucei.

Francisco K, Monti L, Yang W, Park H, Liu L, Watkins K Bioorg Med Chem Lett. 2023; 81:129123.

PMID: 36608774 PMC: 10072319. DOI: 10.1016/j.bmcl.2023.129123.

References

Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J . Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem. 2009; 17(6):2623-31. DOI: 10.1016/j.bmc.2008.10.044. View

Perez-Molina J, Molina I . Chagas disease. Lancet. 2017; 391(10115):82-94. DOI: 10.1016/S0140-6736(17)31612-4. View

Katsuno K, Burrows J, Duncan K, Hooft van Huijsduijnen R, Kaneko T, Kita K . Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat Rev Drug Discov. 2015; 14(11):751-8. DOI: 10.1038/nrd4683. View

Vieira T, Dos Santos I, Silva T, Martins C, Crotti A . Antimicrobial Activity of Monoketone Curcuminoids Against Cariogenic Bacteria. Chem Biodivers. 2018; 15(8):e1800216. DOI: 10.1002/cbdv.201800216. View

Romanha A, de Castro S, Soeiro M, Lannes-Vieira J, Ribeiro I, Talvani A . In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010; 105(2):233-8. DOI: 10.1590/s0074-02762010000200022. View

Alkhaldi A, Creek D, Ibrahim H, Kim D, Quashie N, Burgess K . Potent trypanocidal curcumin analogs bearing a monoenone linker motif act on trypanosoma brucei by forming an adduct with trypanothione. Mol Pharmacol. 2014; 87(3):451-64. DOI: 10.1124/mol.114.096016. View

Chauhan I, Rao G, Shankar J, Chauhan L, Kapadia G, Singh N . Chemoprevention of Leishmaniasis: In-vitro antiparasitic activity of dibenzalacetone, a synthetic curcumin analog leads to apoptotic cell death in Leishmania donovani. Parasitol Int. 2018; 67(5):627-636. DOI: 10.1016/j.parint.2018.06.004. View

Guarner J . Chagas disease as example of a reemerging parasite. Semin Diagn Pathol. 2019; 36(3):164-169. DOI: 10.1053/j.semdp.2019.04.008. View

Martinez-Peinado N, Cortes-Serra N, Torras-Claveria L, Pinazo M, Gascon J, Bastida J . Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity. Parasit Vectors. 2020; 13(1):299. PMC: 7288428. DOI: 10.1186/s13071-020-04171-6. View

10.

Raether W, Seidenath H . The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann Trop Med Parasitol. 1983; 77(1):13-26. DOI: 10.1080/00034983.1983.11811668. View

11.

Machado F, Martins G, Aliberti J, Mestriner F, Cunha F, Silva J . Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation. 2000; 102(24):3003-8. DOI: 10.1161/01.cir.102.24.3003. View

12.

Chainani-Wu N . Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003; 9(1):161-8. DOI: 10.1089/107555303321223035. View

13.

Tamvakopoulos C, Dimas K, Sofianos Z, Hatziantoniou S, Han Z, Liu Z . Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 2007; 13(4):1269-77. DOI: 10.1158/1078-0432.CCR-06-1839. View

14.

Marathe S, Dasgupta I, Gnanadhas D, Chakravortty D . Multifaceted roles of curcumin: two sides of a coin!. Expert Opin Biol Ther. 2011; 11(11):1485-99. DOI: 10.1517/14712598.2011.623124. View

15.

Aggarwal M, Chacko K, Kuruvilla B . Systematic and comprehensive investigation of the toxicity of curcuminoid‑essential oil complex: A bioavailable turmeric formulation. Mol Med Rep. 2015; 13(1):592-604. PMC: 4686098. DOI: 10.3892/mmr.2015.4579. View

16.

Pan M, Huang T, Lin J . Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999; 27(4):486-94. View

17.

Pena I, Manzano M, Cantizani J, Kessler A, Alonso-Padilla J, Bardera A . New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep. 2015; 5:8771. PMC: 4350103. DOI: 10.1038/srep08771. View

18.

Rolon M, Peixoto de Abreu Lima A, Coronel C, Vega M, Pandolfi E, Rojas de Arias A . The efficacy of new 2,5-dihydroxybenzyl derivatives against Trypanosoma cruzi, Leishmania infantum and Leishmania braziliensis. J Infect Dev Ctries. 2020; 13(6):565-576. DOI: 10.3855/jidc.10622. View

19.

Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A . Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther. 2006; 5(10):2563-71. DOI: 10.1158/1535-7163.MCT-06-0174. View

20.

Pal C, Bandyopadhyay U . Redox-active antiparasitic drugs. Antioxid Redox Signal. 2011; 17(4):555-82. DOI: 10.1089/ars.2011.4436. View